一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括Cryo-Thermal Ablation；Toripalimab；Platinum-based doublet chemotherapy，当前状态为招募中。登记地点显示中国成都、泸州、Meishan、南充等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Cryo-Thermal Ablation；Toripalimab；Platinum-based doublet chemotherapy · II 期
登记条件中文摘要
年龄范围：18岁至80岁
登记的基本范围为不限性别，年龄18岁至80岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The Third People's Hospital of Chengdu · 成都
- Sichuan Cancer Hospital & Institute · 成都
- West China Hospital, Sichuan University · 成都
- Public Health Clinical Center of Chengdu · 成都
- The Affiliated Hospital of Southwest Medical University · 泸州
- Meishan People's Hospital · Meishan
- Affiliated Hospital of North Sichuan Medical College · 南充
- Suining Central Hospital · Suining
- Zigong Fourth People's Hospital · Zigong
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Diagnosis, Stage, and Resectability
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
- Clinical stage IB-IIIB according to the 9th edition IASLC/AJCC TNM classification.
- For stage IB disease, only patients with a maximum tumor diameter of 4.0 cm (cT2aN0M0) are eligible.
- The disease must be considered resectable by multidisciplinary team (MDT) assessment with curative-intent surgery planned after neoadjuvant treatment.
- The primary lung lesion must be technically amenable to percutaneous biopsy and CT-guided Cryo-Thermal Ablation..
- No prior systemic or local anti-tumor therapy for the current NSCLC.
- 2. Age, Performance Status, and General Condition
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07855965；登记信息更新于 2026-10-02；本站同步于 2026-10-08。